Zacks.com on MSN5h
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyShares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback